Skip to content
WeighLab
Menu
Ranked #279 · Grade C

Hers review

Hers (Hims & Hers Health, NYSE: HIMS) now sells only FDA-approved branded GLP-1 medications for weight loss — Wegovy, Zepbound, Ozempic, Mounjaro, and the new orforglipron pill 'Foundayo' — rather than compounded semaglutide.

Visit Hers Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. See our disclosure.
Semaglutide
$348/mo (brand Wegovy, plus a separate fee)
Tirzepatide
$448/mo (brand Zepbound, plus a separate fee)
Coverage
All 50 states
Brand-name
Yes

Semaglutide · modeled / year

$4,176

Tirzepatide · modeled / year

$5,376

Pricing verified August 2026

The Index scorecard

Hers scored on our six Cost-Efficiency Index factors. See the methodology.

Normalized Cost/Month25/100
Price Transparency64/100
Nationwide Access86/100
Formulation Options84/100
Clinical Oversight59/100
Contract Flexibility41/100

Where the value is

  • Sells only FDA-approved branded medications (Wegovy, Zepbound, Ozempic, Mounjaro) rather than compounded versions
  • Multiple formats per drug (pill vs pen/vial), including a newer pill option and microdosing plan
  • Large, publicly traded parent (Hims & Hers Health) with an established clinical/support infrastructure

The tradeoffs

  • The advertised 'From $X/mo' price is medication-only — a mandatory membership fee ($39 first month, then $149/mo, billed separately) is layered on top and roughly doubles the real steady-state monthly cost
  • No compounded, lower-cost semaglutide/tirzepatide option was found on the current site
  • The membership fee 'does not include or guarantee a prescription,' so it can recur even in a month without a fresh prescription
  • FDA issued Hims & Hers Health, Inc. dba Hers a warning letter in September 2025; the letter is public in FDA's warning-letter database

The bottom line

Best for: Cost-first shoppers who want brand-name FDA-approved GLP-1 access with a mainstream telehealth name. Hers (Hims & Hers Health, NYSE: HIMS) now sells only FDA-approved branded GLP-1 medications for weight loss — Wegovy, Zepbound, Ozempic, Mounjaro, and the new orforglipron pill 'Foundayo' — rather than compounded semaglutide.

Ranked #279 of 539 providers on the Cost-Efficiency Index — see our #1 pick, CoreAge Rx, for comparison.

Compare with other providers

All 538 other providers we've modeled, in Cost-Efficiency Index order. See the ranked alternatives to Hers.

The 24 programs nearest this one

Pricing, states and verification reflect Hers's public disclosures at last review; the Cost-Efficiency Index is our editorial judgment per the methodology. Prices change — confirm on Hers's site. Not medical advice; see our disclosure.

← Back to the value leaderboard